Skip to main navigation Skip to search Skip to main content

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

  • for the
  • Lungenfachklinik Immenhausen
  • Aix-Marseille Université
  • Genentech, Inc
  • University of Campania Luigi Vanvitelli
  • Asklepios Klinik St. Georg
  • Wayne State University
  • Aichi Cancer Center Hospital and Research Institute
  • Maria Sklodowska-Curie Institute of Oncology
  • Hospital Regional Universitario Carlos Haya
  • AOU San Gerardo
  • Minnesota Oncology
  • Kaiser Permanente
  • Pontifícia Universidade Católica do Rio Grande do Sul
  • University of California at Los Angeles
  • Centro Internacional de Estudios Clinicos
  • IRCCS Istituto Europeo di Oncologia - Milano
  • Istanbul University - Cerrahpaşa
  • Seoul National University
  • University of California at Davis

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology